Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
- Ferhanoglu, Burhan
- Altuntas, Fevzi
- Elverdi, Tugrul
- Kaynar, Leylagul
- Ayyildiz, Orhan
- Yonal Hindilerden, Ipek
- Goksoy, Hasan Sami
- Izmir Guner, Sebnem
- Gunes, Ahmet Kursad
- Sonmez, Mehmet
- Kurt Yuksel, Meltem
- Civriz Bozdag, Sinem
- Ozkurt, Zubeyde Nur
- Toptas, Tayfur
- Dogu, Mehmet Hilmi
- Salim, Ozan
- Saydam, Guray
- Yavasoglu, Irfan
- Ayli, Meltem
- Ozet, Gulsum
- Albayrak, Murat
- Birtas Atesoglu, Elif
- Toprak, Selami K
- Yildirim, Rahsan
- Mehtap, Ozgur
- Akay, Olga Meltem
- Ozbalak, Murat
- Pehlivan, Mustafa
- Yildiz, Birol
- Uzay, Ant
- Yigenoglu, Tugce Nur
- Kalayoglu Besisik, Sevgi
- Nalcaci, Meliha
DOIAbstract
The AETHERA trial reported an increased progression-free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high-risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Thus, we aimed to determine the impact and safety of BV as maintenance after ASCT in real-world patients. Seventy-five patients with relapsed/refractory HL started on BV consolidation therapy after ASCT due to high risk of relapse, between January 2016 and July 2019, from 25 institutions, were included in the study. The median follow-up time was 26 months. The most common high-risk features were primary refractory or relapsed disease <12 months (n = 61), lack of complete response (CR) to the last salvage regimen (n = 51), an...
Add to ORKG